The three main problems addressed by the P-Shot® included erectile dysfunction (ED), Peyronie’s disease (PD), and lichen sclerosus (BXO). Though the prevalence of these problems in New Zealand could vary from that seen in the United Kingdom or the United States, in the US & UK, around 3% of men suffer with Peyronie’s disease with the prevalence of ED ranging from around 10% for men in their 40’s up to around 50% for men over 60. The prevalence of BXO varies greatly in the literature but could be at least 5%.
The usual treatments for these problems can be both frustrating and without correcting the underlying pathophysiology. For ED, neither penile implants, Viagra®, papaverine penile injections, nor vacuum pump therapy correct the underlying pathology of neurovascular disease. J Urol. 2003 Aug;170
With Peyronie’s disease, surgery can leave the penis shorter, risks ED, and the Peyronie’s can reappear, post op, at a new location on the penis—frustrating for both doctor and patient. Injectables for Peryonie’s disease have been not reliable until Xiaflex. But Xiaflex is a fifty-thousand US-dollar series of injections and carries with it the risk of penile fracture. Vacuum pump therapy helped 51% avoid surgery in one series, leaving the other half to need surgery.
For BXO, steroid creams may be used, but often require long term use. The definitive treatment, circumcision may still not be curative nor is it desired by some men.
So, for all three problems, there could be a need for another treatment option to used alone or in concert with the present therapies.
Platelet rich plasma has been the subject of over 9,000 research papers referenced on PubMed in the areas of wound healing, remodeling of scar tissuehttps://www.ncbi.nlm.nih.gov/pmc/?term=platelet+rich+plasma+scar+treatment, down regulating the autoimmune responsehttps://www.ncbi.nlm.nih.gov/pmc/?term=platelet+rich+plasma+autoimmune, regeneration of nerve tissue, helping prevent infection, and now research showing help with the improvement of the male and female genitalia.
For example, Dr. R. Virag, the vascular surgeon who helped develop the idea of papaverine injections for erectile dysfunction, is doing studies for the use of PRP in the treatment of both PD & ED e-mémoires de l'Académie Nationale de Chirurgie, 2014, 13 (3) : 096-100 .
One study, he recently published, showed that PRP injections helped with PD better than Xiaflex and with fewer side effects (the side effect of the PRP is that erectile function improves) http://www.oatext.com/evaluation-of-the-benefit-of-using-a-combination-of-autologous-platelet-rich-plasma-and-hyaluronic-acid-for-the-treatment-of-Peyronies-disease.php .
Other studies of PRP - penile injections have shown improvement in BXO  https://link.springer.com/article/10.1007%2Fs11255-017-1523-0 and ED https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754585/, help with size https://www.jsm.jsexmed.org/article/S1743-6095(16)30656-7/fulltext, and with nerve repair post prostate surgery https://www.ncbi.nlm.nih.gov/pubmed/?term=platelet+rich+plasma+nerve+penis
In over 9,000 papers published on PubMed about the use of PRP, there has been not one report of serious infection, granuloma formation, neoplasia, fibrosis, or necrosis.
Dr Mark Morunga